美股異動 | 內克塔治療(NKTR.US)跌36.85% 未能達到研究目標 和施貴寶停止癌症聯合治療試驗
格隆匯4月18日丨內克塔治療(NKTR.US)跌36.85%,報3.89美元。該公司和百時美施貴寶(BMY.US)週四晚些時候表示,由於未能達到他們的研究目標,他們將停止所有評估bempegaldesil和Opdivo作為潛在癌症聯合療法的試驗。兩家公司表示,對腎癌客觀緩解率的分析顯示,與酪氨酸激酶抑制劑對照組相比,該療法沒有臨牀益處。他們説,公司還將停止對肌肉浸潤性膀胱癌、兒科腫瘤和尿路上皮癌的治療測試。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.